Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Your Path to Better Medical Knowledge Starts Here – FREE Registration!

Become part of a global network of healthcare professionals enhancing patient outcomes with FREE access to our mobile-friendly medical education platform. Stay up-to-date with the latest scientific advancements, delivered in concise formats, so you can learn anytime, anywhere, at your own pace.

Sign up today and get immediate access to:

  • 1000’s topical and insightful peer-reviewed journal articles

  • 100’s of hours of news, congress highlights, and expert insights from key opinion leaders

  • 10 major therapy areas packed with the latest scientific advances

  • Concise email updates and newsletters so you never miss out

It only takes a minute to register and it’s free (forever) to all healthcare professionals.

touchOPHTHALMOLOGY touchOPHTHALMOLOGY

Register Now!

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

  • Save your progress for video
  • Keep track of your CME credits
  • Add personalised learning notes
  • Receive updates from course leaders and faculty
  • Be the first to hear about new and exciting interactive learning opportunities
Close Popup